RxDoctor Payments Data

Craig Hoover, MD

Interventional Cardiology · Tucson, AZNPI 1114905973

Payments from drug & device makers

$20,098in general payments, 2019–2025

Across 267 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$7K
  • Abiomed$4K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • Philips North America LLC$1K
  • Medtronic$870
  • plus $2K from 11 others

What the payments were for

  • Speaking & faculty fees$6,60033%
  • Travel & lodging$3,23116%
  • Food & beverage$10,26751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,098 in reported general payments places this provider in the 60th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$118,814
Medicare patients
587
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$293,051
XareltoRivaroxaban161$215,948
EntrestoSacubitril/Valsartan123$173,884
JardianceEmpagliflozin101$113,645
Repatha SyringeEvolocumab21$25,822
FarxigaDapagliflozin Propanediol24$22,119
Repatha SureclickEvolocumab11$6,898
Nebivolol Hcl36$4,569
Flecainide Acetate71$3,248
Rosuvastatin Calcium218$3,102
Metoprolol Succinate298$2,973
Carvedilol262$2,234
Valsartan110$2,185
Atorvastatin Calcium253$2,037
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$1,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$276$293,051226 claims
Johnson & JohnsonXarelto$425$215,948161 claims
NovartisEntresto$7,344$173,884123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →